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ABSTRACT
Objective: To provide guidance on standards for reporting studies of diagnostic test accuracy for
dementia disorders.
Methods: An international consensus process on reporting standards in dementia and cognitive
impairment (STARDdem) was established, focusing on studies presenting data from which sensi-
tivity and specificity were reported or could be derived. A working group led the initiative through
4 rounds of consensus work, using a modified Delphi process and culminating in a face-to-face
consensus meeting in October 2012. The aim of this process was to agree on how best to sup-
plement the generic standards of the STARD statement to enhance their utility and encourage
their use in dementia research.
Results:More than 200 comments were received during the wider consultation rounds. The areas at
most risk of inadequate reportingwere identified and a set of dementia-specific recommendations to
supplement the STARDguidancewere developed, including better reporting of patient selection, the
reference standard used, avoidance of circularity, and reporting of test-retest reliability.
Conclusion: STARDdem is an implementation of the STARD statement in which the original
checklist is elaborated and supplemented with guidance pertinent to studies of cognitive disor-
ders. Its adoption is expected to increase transparency, enable more effective evaluation of diag-
nostic tests in Alzheimer disease and dementia, contribute to greater adherence to methodologic
standards, and advance the development of Alzheimer biomarkers. Neurology® 2014;83:364–373
GLOSSARY
AD 5 Alzheimer disease; CONSORT 5 Consolidated Standards of Reporting Trials; DTA 5 diagnostic test accuracy; MCI 5
mild cognitive impairment; STARD 5 Standards for Reporting of Diagnostic Accuracy.
Over the past decade, there has been an impressive increase in the number of reports published
on Alzheimer disease (AD) and dementia biomarkers, describing both proof-of-concept and
diagnostic test accuracy (DTA) studies. New diagnostic criteria proposed in the United States
and in Europe place greater emphasis on the use of biomarkers and imaging techniques in
the diagnosis of AD (in both symptomatic and asymptomatic subjects).1–4 An amyloid PET
ligand has been licensed on the basis of its utility in excluding a diagnosis of AD.5,6 “Appropriate
Use” criteria have since been proposed that suggest routine use of florbetapir PET scanning in
mild cognitive impairment (MCI), but the lack of evidence for enhancing diagnostic certainty or
for predicting progression has been acknowledged.7 The European Medicines Agency supports
the use of CSF biomarkers (b-amyloid 42 and tau) to enrich clinical populations with prodromal
AD.8 Numerous other potential biomarkers are in development.
Diagnostic tests for diseases that may cause cognitive problems are not restricted to biochemical
and neuroimaging biomarkers. There are a variety of clinical assessment scales, both for “screening”
and “diagnosis,” such as the Alzheimer’s Disease Assessment Scale,9 Montreal Cognitive Assess-
ment,10 and the Addenbrooke’s Cognitive Examination–Revised.11 At present, there is little guid-
ance on the optimal assessment scale for a particular purpose or setting; this has resulted in
considerable variation in approaches to cognitive testing. As many countries move toward large-
scale cognitive screening of older adults,12 there is considerable need for studies of DTA.13,14
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In dementia, diagnostic studies can be
divided into proof-of-concept studies (whether
a test result is different in healthy controls vs
dementia patients) and studies investigating
the clinical applicability of a new diagnostic test.
For the latter, there are 3 main questions:
1. Are those with certain test results more likely to
have a particular form of dementia, for example,
Lewy body dementia, than persons with other test
results (differential diagnosis)?
2. Are those with certain test results more likely to
progress to, for example, AD dementia, than per-
sons with other test results (delayed determination
or prediction)?
3. Does the test provide incremental benefit in the
diagnostic workup, considering ease of administra-
tion of the test, costs, and burden for the patient?
In this context, the quality of reporting of
DTA studies is particularly important. Poor
or inconsistent reporting can hamper effective
evaluation of study methods, assessment of
potential for bias, and interpretation of the re-
sults.15–18 It also limits the ability to synthesize
data across studies, precluding methodologi-
cally sound meta-analyses. Guidelines for re-
porting standards in other contexts,19 such as
the Consolidated Standards of Reporting Trials
(CONSORT) statement, are effective in raising
reporting standards and, indeed, can also drive
improvements in standards of trial design.20–22
In 2003, Bossuyt et al.23 published the
STARD statement: Standards for Reporting
of Diagnostic Accuracy studies, aiming to
“improve the accuracy and completeness of
reporting of studies of diagnostic accuracy, to
allow readers to assess the potential for bias in
the study (internal validity) and to evaluate its
generalizability (external validity).”24 To date,
more than 200 scientific journals have become
STARD “adopters.” Although the impact
of STARD may not yet be comparable to
CONSORT, STARD has raised standards of
reporting in diagnostic accuracy studies.25
Despite this, a recent systematic review found
that, within the field of dementia, the majority
of reports of diagnostic biomarker studies were
missing important information, particularly for
blinding of results of either the biomarker or ref-
erence standard, handling of missing data, sam-
ple selection methods, and test reproducibility.26
Although DTA studies in dementia are similar
to those in any field, some features specific to
dementia research are not fully addressed in the
STARD criteria. Therefore, we aimed to iden-
tify aspects of reporting that are particularly
important in the context of AD and dementia,
produce dementia-specific supplementary guid-
ance to STARD, and thereby enhance use (and
utility) of STARD for dementia studies.
METHODS The STARDdem Initiative sought to establish an
international consensus on reporting standards for DTA studies
in dementia, highlighting the most important issues and identify-
ing any areas in which additional reporting recommendations
might enhance the usefulness of the STARD guideline. The
method used was derived from guidance on effective implemen-
tation of reporting standards published by the EQUATOR
(Enhancing the Quality and Transparency of Health Research)
Network,27 which proposes a step-wise development approach
and deems a consensus process to be “a crucial characteristic”
of developing reporting guidelines.22 We adapted the guidance
leading to a development process comprising 3 broad phases: (1)
evaluation, (2) drafting with widespread discussion and feedback
using a modified Delphi technique,28 and (3) delivery. This
report describes the first 2 phases and itself constitutes part of
the delivery phase.
Phase 1: Evaluation. We conducted a comprehensive literature
review on biomarker DTA studies in dementia, focusing on studies
that included patients with cognitive impairment (but no demen-
tia) at baseline and used progression to dementia of the AD type
as a reference standard (for methods, see Noel-Storr et al.26).
Applying STARD, we assessed the quality of reporting in all
identified DTA studies by calculating the percentage of studies
complying with each of the STARD items.23
Phase 2: Drafting and discussion. An international and mul-
tidisciplinary working group of dementia experts and methodol-
ogists was established, organized by the Cochrane Dementia and
Cognitive Improvement Group.29 The objectives of this group
were to (1) define the scope of STARD for dementia, (2) assess
the applicability of existing reporting guidelines (STARD) to demen-
tia, (3) draft dementia-specific supplementary recommendations,
Figure Phases and rounds of the STARDdem Consensus Initiative
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and (4) seek feedback and consensus from the dementia research
community.
In round 1 of phase 2 (see the figure), the working group held a
series of 4 meetings (one face-to-face, 3 teleconferences). Before
each, members independently assessed 3 papers using the STARD
tool, rating whether each STARD criterion was met and with the
option to record free text comments. The 12 papers were randomly
selected from studies identified by searches for DTA systematic
reviews in progress by the Cochrane Dementia and Cognitive
Improvement Group.30 Omissions, agreements, and disagreements
were identified and discussed at these meetings. This stage of the
process highlighted areas in which there was lack of clarity about
what constituted “clear” or “poor” reporting within a dementia
context, and hence identifying a number of focus areas for STARD-
dem. Supplementary guidance in these areas was drafted, and
examples of adequate/clear reporting were identified from dementia
diagnostic research for each relevant item. Round 1 also helped to
highlight the different types of bias that can arise in dementia
studies (see table 1). Bias, in this context, is defined as a systematic
error, often unintentional and sometimes unavoidable, in an
observed measurement from the true value. If bias existed, a study
would consistently over- or underestimate the true accuracy param-
eters (such as test sensitivity or specificity) were the study to be
replicated and repeated.
In round 2 (figure), draft additional guidance and examples,
together with the generic STARD guidance, were uploaded to the
STARDdem Web site.31 More than 350 individuals were invited
to comment via the Web site. These individuals had been iden-
tified as the following: corresponding authors of diagnostic stud-
ies using imaging, biochemical biomarkers, or neuropsychiatric
Table 1 Sources of bias
Bias Explanation Example
Test performance bias
Context bias Readers are more likely to interpret
results from (subjective) tests as
abnormal in settings with higher
prevalence of the target condition
In an early-onset dementia clinic with a
high prevalence of FTD, apathy may be
more likely to be seen as supportive of
this diagnosis than in an older
population
Clinical review bias Interpretations are influenced by
providing additional clinical information
to interpreters
When clinical information about
cognitive function may influence a
radiologist’s assessment of hippocampal
atrophy
Diagnostic review bias Knowing the result of the index test
while interpreting the reference
standard. Leads to inflated diagnostic
accuracy
When knowledge of a CSF Ab and/or tau
test result may influence a clinician
making a diagnosis of AD
Verification bias If the result of the index test influences
the decision to order the reference
standard test
Common in dementia research. Would
occur if PiB-PET is the index test, AD at
autopsy is the reference standard, and
the decision to conduct an autopsy was
(partly) based on the PET result
Incorporation bias If the index test forms part of the
reference standard, this leads to
circularity and inflated diagnostic
accuracy
Very common in dementia research, for
example, when the index test is a test of
episodic memory and the reference
standard is a clinical diagnosis of AD
Test review bias Knowledge of the result of the reference
standard while interpreting the index
test. Leads to inflated diagnostic
accuracy
More common in cross-sectional
studies. For example, knowledge of a
patient’s diagnosis may influence a
radiologist’s interpretation of an amyloid
PET scan
Patient-based bias
Limited challenge bias Patients with a condition known to
adversely affect the way the test works
are excluded. Leads to inflated
diagnostic accuracy
Common. Occurs when patients likely to
be more challenging to diagnose are
excluded, for example, applying a
potential index test for DLB to a sample
from which “possible DLB” subjects have
been excluded. (Could also be an
example of spectrum bias—see below)
Selection bias If participants are excluded based on
specific characteristics
Common. Occurs, for example, when
patients with cerebrovascular lesions on
MRI are excluded from a study
investigating a biomarker for AD
although the population to whom the
test may be applied in daily practice will
include many patients with some
cerebrovascular lesions
Spectrum bias Demographic and clinical features,
including disease severity of the study
population, influence diagnostic
accuracy
Common. For example, studying a
relatively young group of patients (e.g.,
,70 y) who are likely to differ in many
ways from the older population who
constitute the majority of patients with
dementia
Abbreviations: Ab 5 b-amyloid; AD 5 Alzheimer disease; DLB 5 dementia with Lewy bodies; FTD 5 frontotemporal
dementia; PiB 5 Pittsburgh compound B.
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tests; presenting authors of relevant oral presentations and posters
identified from the abstract books of the Alzheimer’s Association
International Conference 2012 and Clinical Trials in Alzheimer’s
Disease conference 2012; editors of journals who publish signif-
icant numbers of diagnostic studies in dementia; and DTA meth-
odologists. The site was open access with an encouraged
branching dissemination strategy whereby participants shared
the site address with other interested parties. Participants could
post general feedback and/or comments on specific items, anon-
ymously if they wished. This period of feedback was open for 2
months. The comments obtained were all discussed in the work-
ing group during a further 3 teleconferences, and revised
dementia-specific additions to STARD were drafted (round 3,
figure).
Round 4 (figure) consisted of a half-day consensus meeting,
held in October 2012. The meeting had 2 main aims: (1) to reach
consensus on the reporting of items of key significance in dementia
DTA studies and on the choice of examples to illustrate good
reporting, and (2) to decide on the best method for disseminating
the outcome of the process and ensuring its adoption by the
research community. The meeting ran as both a face-to-face meet-
ing and Web conference to try to maximize attendance and partic-
ipation. Participants comprised 40 individuals, with key groups
represented by researchers/authors in this field and journal editors.
After this meeting, the working group then produced a final version
of the STARDdem supplementary recommendations.
RESULTS See appendix (table e-2) on the Neurology®
Web site at Neurology.org for key definitions pertinent
to studies of DTA.
Phase 1. The results of the STARD assessment for
studies included in our systematic review have been
reported in detail elsewhere.26 In brief, this review
found that of the 142 studies identified, there was
marked variation in the quality of reporting between
several STARD items. Items particularly poorly re-
ported or referenced are listed in table 2.
Phase 2. STARD is applicable to studies in which the
results of one or more (index) tests are compared with
the results of a reference standard applied to the same
subjects, allowing production of a 2 3 2 table from
which estimates of test accuracy—usually sensitivity
and specificity—may be obtained. Binary diagnostic
categories retain core utility as the basis for prognosis,
treatment, management, and legal decision-making: the
fact that the pathology and symptoms of dementias
occur on a spectrum does not negate the need for the
clear delineation of thresholds in index tests and for
categorical reference standards. Correlations between
continuous variables (e.g., biomarker level and
cognitive decline) are of value for establishing etiology
and point to potential as a diagnostic test, but do not
guide clinicians or reimbursers about when the benefits
of starting treatment outweigh the risks and costs.
Although most diagnostic test studies are cross-
sectional by design, in dementia studies, the reference
standard of “progression from MCI to dementia” is
frequently used. These “delayed verification” studies
(entailing some additional complexities of design)
were included if 2 3 2 data were presented or could
be derived. Studies were included regardless of the
phase of development of the test.
The initial draft of reporting items, produced by
the working group for consultation, may be viewed
on the STARDdem Web site.31 During the open
comment period of 2 months, more than 200 com-
ments were posted by clinicians, statisticians, meth-
odologists, neuropsychologists, molecular biologists,
clinical chemists, and radiologists. Based on the com-
ments of the working group, the most important
items to address were (1) the description of the pop-
ulation under study, (2) reporting of the operational-
ization and application of the reference standard, (3)
identification of potential incorporation bias or “cir-
cularity” when the index test forms a part of the ref-
erence standard (e.g., a neuropsychological test that
also contributes to the diagnosis of dementia), and (4)
reporting of test-retest reliability.
The second draft, which was circulated to consensus
meeting participants, may also be viewed on the
STARDdem Web site.31 After the discussion at the
consensus meeting, a final version was produced in
Table 2 STARD items poorly reported or
referenced
Item no. Topic
Partial or not
reported, %
5 Participant sampling 46
10 Training and expertise
Index test 73
Reference standard 77
11 Blinding
Index test 77
Reference standard 36
13 Methods for calculating test
reproducibility
Index test 76
Reference standard
(operationalized)
96
14 Study dates 72
16 Reasons for subjects meeting
inclusion who did not undergo
index test or reference
standard
60
20 Presence or absence of
adverse events
97
22 Handling of missing or
indeterminate data
82
23 Variability of diagnostic
accuracy between subgroups:
participants, readers, or
centers
64
24 Estimates of test
reproducibility
Index test 82
Reference standard 96
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Table 3 STARDdem checklist for the reporting of diagnostic accuracy studies in dementia
Section, topic, and
item no. STARD checklist item Points of particular relevance to dementia
Title/abstract/
keywords
1 Identify the article as a study of
diagnostic accuracy (recommend MeSH
heading “sensitivity and specificity”)
Studies reporting a sensitivity/specificity or 2 3
2 data derivable fall within the scope of
STARDdem and should be indexed accordingly
Introduction
2 State the research questions or study
aims, such as estimating diagnostic accuracy
or comparing accuracy between tests or
across participant groups
Some studies describing aims related to
“prognosis” or “prediction” may also fall within
the remit of STARDdem. Report test purpose:
“stand-alone” test or as an addition to other
tests or clinical criteria
Methods
Participants
3 The study population: the inclusion and
exclusion criteria, setting and locations
where data were collected. See also item
4 on recruitment and item 5 on sampling
Key inclusion criteria: (1) demographic,
especially age; (2) cognition- or disease-related
criteria. Accurate description of the target
sample is required including reporting criteria
used to define the study population. Report
referral pathways, precise locations of patient
recruitment, where index test and reference
standard were performed. For secondary/
tertiary settings, helpful to report the medical
subspecialty or hospital department (e.g.,
psychiatry, neurology). Diagnostic accuracy
studies in dementia are often nested within
larger cohort studies. If this is the case, then the
targeted population for the cohort study and the
method of selection into the cohort should be
described and/or the parent study cited
4 Participant recruitment: Was recruitment
based on presenting symptoms, results
from previous tests, or the fact that the
participants had received the index tests
or the reference standard? See also item
5 on sampling and item 16 on participant
loss at each stage of the study
Report whether those in intermediate categories
(e.g., possible AD or possible DLB) were excluded
5 Participant sampling: Was the study population
a consecutive series of participants defined by
the selection criteria in items 3 and 4? If not,
specify how participants were further selected.
See also item 4 on recruitment and item 16 on
participant loss
Planned analyses showing how characteristics
of the subgroup entering the study differ from
the eligible population are strongly
recommended (i.e., if a convenience sample has
been used because of the invasive nature of the
test or tests)
6 Data collection: Was data collection planned
before the index test and reference standard
were performed (prospective study) or after
(retrospective study)?
Authors should report the timing of the analysis
plan regarding data collection: Was the analysis
plan set out in a protocol before index and
reference standards were performed? If not,
when was the analysis plan created?
Test methods
7 The reference standard and its rationale For neuropathologic and clinical reference
standards, the diagnostic criteria used should be
specified. Where relevant, reference should be
made to studies validating the criteria. Report
whether standard consensus clinical criteria
incorporate the index test (incorporation bias
rendering blinding of index test impossible)
8 Technical specifications of materials and
methods involved including how and when
measurements were taken, and/or cite references
for index tests and reference standard. See also
item 10 concerning the person(s) executing
the tests
Use of scales: specify details of administration,
which version. Clinical diagnostic criteria: what
information was available to inform the
diagnoses; how the criteria were applied (e.g., by
individual clinicians, by consensus conference,
by semiautomated algorithm). Imaging and
laboratory tests: specify materials and
instruments, including sample handling and
concordance with any harmonization criteria. In
new assays, describe all steps in detail. Any
particular preparation of participants should be
described
9 Definition of and rationale for the units, cutoffs,
and/or categories of the results of the index tests
and the reference standard
Justify any cutoffs used, because these may
vary with clinical context
Continued
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Table 3 Continued
Section, topic, and
item no. STARD checklist item Points of particular relevance to dementia
10 The number, training, and expertise of the
persons executing and reading the index tests
and the reference standard. See also item 8
Especially where subjective judgments are
involved, e.g., the interpretation of neuroimaging
results. Report inter- and intrarater agreement.
Reference or describe the content of training
materials used. Reference or describe details of
lab certification and harmonized biomarker
assays
11 Whether or not the readers of the index tests
and reference standard were blinded (masked) to
the results of the other test and describe any
other clinical information available to the readers.
See also item 7
Also, the index test may form a part of the
reference standard. This is often referred to as
incorporation bias and renders blinding of the
index test impossible
Statistical
methods
12 Methods for calculating or comparing measures
of diagnostic accuracy, and the statistical methods
used to quantify uncertainty (e.g., 95% confidence
intervals)
13 Methods for calculating test reproducibility,
if done
Applies to the reference standard as well as to
the index test. Both should be reported/
adequately referenced. Report interrater and
test-retest reliability of reference standard as
established in the study being reported, rather
than simply referring to other studies in which
reproducibility has been established. The
training that image readers receive should be
carefully described. Studies in which the
accuracy of “majority” judgments are reported
should also report data for the minority
judgments. Reports of the impact of training
should clearly describe the characteristics of the
sample used for training and whether it is
representative of the group to which the test will
be applied
Results
Participants
14 When study was performed, including beginning
and end dates of recruitment
Pertinent particularly to longitudinal (delayed
verification) studies, authors should report
recruitment dates of the study (not to be
confused with recruitment dates of the wider
cohort study from which it might be drawn), and
the beginning (first participant) and end (last
participant) dates of the periods during which
the index test(s) and reference standard were
performed. Report the period for the index test
and period for the reference standard
separately if it is not clear
15 Clinical and demographic characteristics of the
study population (at least information on age,
sex, spectrum of presenting symptoms). See
also item 18
Report key demographic variables: age, sex, and
education. Report age distribution of sample in
detail. Ethnicity and genetic factors (e.g., APOE
genotype) may also be particularly important. The
cognitive characteristics are covered in item 18
16 The number of participants satisfying the criteria
for inclusion who did or did not undergo the index
tests and/or the reference standard; describe why
participants failed to undergo either test (a flow
diagram is strongly recommended). See also
items 3–5
Test results
17 Time interval between the index tests and
the reference standard, and any treatment
administered in between
Specify the follow-up period for all subjects in
relation to their outcomes. It should be specified
whether participants had received any
treatments that might affect disease
progression
18 Distribution of severity of disease (define criteria)
in those with the target condition; other diagnoses
in participants without the target condition
Include a description of the severity of the
target condition at the time the index test is
performed. Usually captured by a cognitive
score and/or duration of symptoms. For delayed
verification studies, report distribution of
severity of disease and the degree of certainty
(such as probable/possible) about the diagnosis
at the time of case ascertainment. Report other
diagnoses (not target condition). Report
relationship of test to other diagnoses
Continued
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the form of brief additions to the concise tabular format
of STARD (see table 3; print version accessible from
table e-1). For 18 of the 25 items, dementia-specific
additions were deemed necessary. Also, dementia-
specific examples of adequate reporting were derived
from the literature and are available in table e-2.
There are 4 key areas central to effective evaluation
of studies of diagnostic tests in dementia and cogni-
tive impairment to which special attention should
be given when reporting results of DTA studies in
dementia and cognitive impairment:
1. Study population: Many DTA studies report on a
highly selected population, e.g., from a tertiary
memory clinic or a sample of convenience. Gener-
alizability to the population with cognitive impair-
ment at large, or even to other speciality clinics,
may be questionable. The report should address
whether that sample was representative in terms
of spectrum of disorders, proportion of cases with
the disease for which the index test is intended, and
severity of cognitive impairment of the population in
whom the test would be applied in practice. If not,
then test accuracy may be over- or underestimated.
2. Reference standard: The current limitations in our
reference standards in dementia are responsible for
some of the inaccuracy and bias that bedevil stud-
ies of test accuracy. The 2 major classes of refer-
ence standard are (1) postmortem verification, and
(2) progression from MCI to dementia due to AD
or other conditions according to clinical criteria.
Both fall short of the ideal and carry risks of
disease misclassifications (bias by the reference
standard). An inconsistently applied reference
standard creates obvious difficulties in effectively
evaluating the performance of a test across studies.
Careful specification of the reference standard(s),
its operationalization, and application are essen-
tial. If more than one reference standard is applied,
the index test results should also be displayed by
the different reference standards.
3. Circularity: “Incorporation bias,” whereby the
index test forms a part of the reference standard,
is common in dementia diagnostic studies. This
is inevitable given the composite nature of the
reference standards and is a particular problem
in the evaluation of neurocognitive tests. Incor-
poration bias is associated with a tendency to
overestimate the value of a specific diagnostic
test. The risk of such bias should be acknowl-
edged and reported.
Table 3 Continued
Section, topic, and
item no. STARD checklist item Points of particular relevance to dementia
19 A cross-tabulation of the results of the index
tests (including indeterminate and missing results)
by the results of the reference standard; for
continuous results, the distribution of the test
results by the results of the reference standard
20 Any adverse events from performing the index
tests or the reference standard
Report all adverse events, even if unlikely to be
related to the diagnostic test performed
Estimates
21 Estimates of diagnostic accuracy and measures
of statistical uncertainty (e.g., 95% confidence
intervals). See also item 12
22 How indeterminate results, missing data, and
outliers of the index tests were handled
23 Estimates of variability of diagnostic accuracy
between subgroups of participants, readers, or
centers, if done
24 Estimates of test reproducibility, if done. See
also item 13
Discussion
25 Discuss the clinical applicability of the study
findings
Discuss differences in age and comorbidity
between the study population and the patients
typically seen in clinical practice. Discuss
whether the reported data demonstrate “added”
or “incremental” value of the index test over and
above other routine diagnostic tests. Identify
stage of development of the test (e.g., proof of
concept; defining accuracy in a typical spectrum
of patients). Discuss the further research
needed to be done to make test applicable to
population in whom likely to be applied in
practice
Abbreviations: AD 5 Alzheimer disease; DLB 5 dementia with Lewy bodies; MeSH 5 Medical Subject Headings; STARD 5
Standards for Reporting of Diagnostic Accuracy.
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4. Reliability: Reporting on the test-retest reliability
is important. Intra- and interobserver variability
may have important effects on neurocognitive
scales. For many of the CSF biomarkers, signifi-
cant intraindividual variation can be found on
repeated testing. In addition, there may be sub-
stantial interlaboratory variability.32,33 Initiatives
are underway to pinpoint and minimize causes
of test variation, particularly for protein bio-
markers.34,35 Clear reporting of test-retest reliabil-
ity should help to complement these efforts.
DISCUSSION It is striking that many of the causes of
bias in studies of DTA are similar to those in clinical
trials: population selection, blinding, missing data
and dropouts, and unreliable outcomes. Other com-
mon causes of bias more specific to DTA studies
are use of healthy controls and mixed reference stand-
ards.15,36 Without full and transparent reporting,
readers are unable to assess the validity of individual
studies, and thus the overall body of evidence available
for a particular test or biomarker. This increases the
risk of misinterpretation and misuse of the test data.37
High-quality reporting is of particular importance as
patients increasingly present early with equivocal
symptoms.12 A diagnosis (or indeed, misdiagnosis) of
such a disease has profound implications for patients
and their families. Although no disease-modifying
treatments or treatments for early-stage illness have
reached clinical practice, it is imperative that, when
they do, confidence in the diagnostic process is high.
At present, the patchy quality of reporting damages the
confidence with which findings from studies of DTA
can be translated and applied to clinical practice.
The STARD guidelines are important in raising
awareness of the key reporting issues in DTA studies.25
However, despite widespread adoption by journals,
our earlier work shows that standards of reporting in
the dementia field are not uniformly high.26 The
STARDdem Consensus Initiative serves to raise aware-
ness of the issues in test accuracy, and emphasizes those
that are particularly important to dementia and cogni-
tive impairment.
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